Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Open-label, Prospective, Single-arm, Single-center Study of Induction of Hypothyroxinemia Adjunct to Conventional Therapies in GBM Patients

NCT02654041 is registered in ClinicalTrials.gov with Musli Thyropeutics Ltd. as lead sponsor.

NCT NCT02654041
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02654041 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Open-label, Prospective, Single-arm, Single-center Study of Induction of Hypothyroxinemia Adjunct to Conventional Therapies in GBM Patients
Lead sponsor
Musli Thyropeutics Ltd.
Phase
Phase 2
Overall status
Terminated
Start date
March 31, 2016
Completion date
June 30, 2017
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme (gbm)